Science and Enterprise

Category: Joint ventures/collaborations

  • Baxter, Takeda Complete Deal on Influenza Vaccines

    Baxter International Inc. in Deerfield, Illinois and Takeda Pharmaceutical Company in Osaka, Japan said today they completed a development, license, and technology transfer agreement to bring Baxter’s Vero cell culture-based influenza vaccines to the Japanese market. This agreement expands on the companies’ current collaborations involving cell-based flu vaccines. Under the agreement, Baxter will exclusively license…

  • Arthritis Drug Protects Against Non-Melanoma Skin Cancer

    A widely used arthritis drug reduces the incidence of non-melanoma skin cancers according to a study published this week in the Journal of the National Cancer Institute. The COX-2 inhibitor celecoxib, approved for the treatment of osteoarthritis, rheumatoid arthritis, and acute pain in adults, led to a 62 percent reduction in non-melanoma skin cancers, which…

  • R&D Collaboration to Discover Drugs for River Blindness

    Anacor Pharmaceuticals in Palo Alto California, the University of California San Francisco’s Sandler Center and the Lindsley F. Kimball Research Institute (LFKRI) of the New York Blood Center established a research and development collaboration to discover new therapies to treat river blindness (onchocerciasis). River blindness is a parasitic disease and the second leading cause of…

  • GSK, Nottinghan Univ. to Collaborate on Green Chemistry

    The BBC is reporting that the global drug manufacturer GlaxoSmithKline (GSK) will build a new lab at the University of Nottingham in the U.K. for research and education in cleaner and safer chemistry processes. The proposal is expected to be presented first as a proof-of-concept in 2011, for construction at the University’s Jubilee Campus, one…

  • Aileron Adds Scripps Chemistry Process for Drug Discovery

    The Scripps Research Institute in San Diego, California and Aileron Therapeutics in Cambridge, Massachusetts said today (30 November) they agreed to add Scripps Research’s molecular chemistry technology known as “click chemistry” to Aileron’s peptide and protein platforms. The agreement provides Aileron exclusive rights to use click chemistry for therapeutics and non-exclusive rights for diagnostics. Click…

  • Laser Measurement Device Deployed for Europe Wind R&D

    Denmark’s National Laboratory for Sustainable Energy, known as Risø DTU, has developed a laser-based instrument package to measure conditions at wind power farms, and that device will now be used across Europe at European Energy Research Alliance research stations and commercial installations. Just one of the devices, called a WindScanner (pictured right) , can produce…

  • Alsace, Québec Consortia to Collaborate on Drug Discovery

    Alsace BioValley, in Illkirch-Graffenstaden, France, a health science cluster and Québec Consortium for Drug Discovery in Nuns’ Island, Québec, Canada, signed in Paris today an agreement for a bilateral partnership to benefit Alsatian and Québec research centers and industries in the health and life sciences. The agreement calls for co-financing of R&D collaborative projects in…

  • University Licenses Nanoparticle Drug Delivery Technology

    The University of British Columbia (UBC) and the Centre for Drug Research and Development (CDRD), both in Vancouver, Canada, said today that Covidien, a Dublin, Ireland provider of health care products, has licensed a drug-delivery platform technology invented by UBC researcher, Pieter Cullis. CDRD provided the development facilities and commercialization services that led to this…

  • U.S., Greece Collaborate on Invasive Weed Defense

    One U.S. export not appreciated overseas is the silverleaf nightshade, an invasive weed from the Americas that has spread to southern Europe, Africa, India, Australia, and elsewhere. The Agricultural Research Service (ARS) of the U.S. Department of Agriculture and the Benaki Phytopathological Institute in Athens, Greece are working together to find a natural way to…

  • Pfizer, Diagnostics Company to Collaborate on Sepsis Tests

    SIRS-Lab,a molecular diagnostics company in Jena, Germany and Pfizer Pharma GmbH in Berlin said today they plan to collaborate in the field of sepsis. The collaboration aims to develop molecular diagnostic tests for early and accurate targeting of anti-infection therapy. Sepsis is a life-threatening illness caused by the body’s response to a bacterial infection. The…